Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

Clinical Study on Track to Complete Accrual in Fourth Quarter 2008

BERKELEY HEIGHTS, N.J., June 24 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. The trial is being led by the EADO in Europe and by the M.D. Anderson Cancer Center, Houston, TX in the U.S.

To date, more than one-third of the expected total number of patients have now been randomized onto the AGENDA trial. A total of 83 sites in 12 countries have been opened in Europe, the U.S., Canada, and Australia. Clinical characteristics of the first 70 patients accrued to AGENDA (not identified by treatment group) were shown to be similar to the biomarker-defined population accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events in AGENDA has been somewhat lower, which probably reflects the routine use of prescribed supportive care for all patients, as well as the double-blind design of AGENDA compared with the open-label design of GM301. Target accrual of 300 patients is expected to complete in the fourth quarter
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... WEST ORANGE , N.J. and NEW BRUNSWICK, N.J., Sept. ... formal affiliation agreement that allows Kessler Foundation and ... to advance biomedical research, education and patient care ... , president and chief executive officer of Kessler ... of New Jersey Health Foundation. "The ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
(Date:9/30/2014)... Ariz. , Sept. 30, 2014 Passport ... North America , has launched FluFree.com, a website ... flu vaccinations. For 20 years, Passport Health ... including the flu. The launch of FluFree.com is designed ... vaccination and the number of people who actually chose ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... 26 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Pharmaceuticals, Inc. (Huxley), which has rights to a ... the rare autoimmune disease Lambert Eaton Myasthenic Syndrome ... Products for Human Use of the European Medicines ...
... PINNACLE Network (TM) Links Thousands of Clinical ... Excellence , WASHINGTON, Oct. 26 The ... of the PINNACLE Network(TM), the first-ever registry-based cardiovascular ... each other and to the ACC,s National Cardiovascular ...
Cached Medicine Technology:BioMarin Acquires Huxley Pharmaceuticals, Inc. 2BioMarin Acquires Huxley Pharmaceuticals, Inc. 3BioMarin Acquires Huxley Pharmaceuticals, Inc. 4BioMarin Acquires Huxley Pharmaceuticals, Inc. 5BioMarin Acquires Huxley Pharmaceuticals, Inc. 6American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 2American College of Cardiology Launches the Nation's First Registry-Based Cardiovascular Practice Network 3
(Date:9/30/2014)... of Maryland-led research team has been awarded a ... of Health (NIH) to develop new imaging technologies ... understanding of how large networks of neurons in ... knowledge will help researchers identify the precise interactions ... like decision-making and speaking, and alterations in these ...
(Date:9/30/2014)... 2014 EverStryke , the permanent match ... SurvivalLife.com along with a free book and class all about ... Michaels, prompting an investigative review. , “Joe Marshall of ... survival and preparation niche, and this product is an excellent ... and survival products that Joe offers on his website to ...
(Date:9/30/2014)... 30, 2014 Elevate , the latest ... better in and out of the gym by providing natural ... the attention of Shane Michaels, prompting an investigative review. ... the reason most people simply just don’t have the ability ... focused at work, getting the motivation to finish a project, ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... providers in Turkey has gone up more than 79 ... The medical tourism company also reported total revenue tripled ... 2012. , The company’s professional strategy has allowed them ... — ultimately designed for patient comfort and privacy — ...
(Date:9/30/2014)... 30, 2014 Hospice & Palliative ... “In Celebration” gala, honoring three outstanding individuals for ... striving to provide extraordinary and dignified comfort, care ... serious or life-limiting illness. , The event was ... NY and recognized William (Bill) J. McGuinness, Director ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2
... New York, NY, August 6, 2009 Comprehensive health reform ... 13 million uninsured young adults ages 19-29 gain coverage, ... who now have coverage would not lose it, according ... coverage to all Americans through expansions in Medicaid and ...
... on medical tourism, exotic destinations , SATURDAY, Aug. 15 ... the U.S. government has a guidebook that could save ... and Prevention has released a new edition of ... as "The Yellow Book" for its distinctive cover, which ...
... , NEW YORK, Aug. 14 Healthcare may be on ... the price you pay at the pharmacy is actually getting the medicine ... to this report from Forest Laboratories at: http://inr.mediaseed.tv/oneClip _ ... Registered journalists can access video, audio, text, graphics and photos for ...
... , , , , ... Board: SNKTY), a Life Sciences company engaged in the research, development ... today announced revenues for its fiscal second quarter ended June 30, ... 31, 2009 and $691,000 reported in the comparable prior year period ...
... impact on cognition, study finds , FRIDAY, Aug. 14 ... difference in mental decline after the age of 70, ... the Aug. 1 issue of the American Journal ... background have an impact on cognitive functioning among the ...
... , Additional 28 New ... WASHINGTON, Aug. 14 Today, Secretary of Veterans Affairs Eric K. ... assistance in 28 additional communities across the country where the Department ... , , "VA is committed to providing high-quality ...
Cached Medicine News:Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 2Health News:Health reform proposals could help 13 million uninsured young adults gain coverage 3Health News:International Travel Health Guidebook Gets Updated 2Health News:Senetek PLC Reports Second Quarter 2009 Financial Results 2Health News:Senetek PLC Reports Second Quarter 2009 Financial Results 3Health News:Senetek PLC Reports Second Quarter 2009 Financial Results 4Health News:Senetek PLC Reports Second Quarter 2009 Financial Results 5Health News:Senetek PLC Reports Second Quarter 2009 Financial Results 6Health News:Rich, Poor See Similar Declines in Old Age 2Health News:Secretary Shinseki Announces Expansion of Counseling for Combat Veterans 2
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: